Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

LOSARTAN IMPURITY D CRS (10 MG)

LOSARTAN IMPURITY D CRS (10 MG)

83857-96-9

DISCOVER
BECLOMETASONE  DIPROPIONATE IMPURITIES F AND N CRS (0.052 MG

BECLOMETASONE DIPROPIONATE IMPURITIES F AND N CRS (0.052 MG

NA

DISCOVER
RIFAXIMIN CRS (160 MG)

RIFAXIMIN CRS (160 MG)

80621-81-4

DISCOVER
RIFAXIMIN FOR SYSTEM SUITABILITY CRS (10 MG)

RIFAXIMIN FOR SYSTEM SUITABILITY CRS (10 MG)

80621-81-4

DISCOVER
LOSARTAN FOR SYSTEM SUITABILITY CRS (0.002 MG)

LOSARTAN FOR SYSTEM SUITABILITY CRS (0.002 MG)

NA

DISCOVER
IOPROMIDE IMPURITY A CRS (0.125 MG)

IOPROMIDE IMPURITY A CRS (0.125 MG)

NA

DISCOVER
BICISATE LABELLING KIT CRS (1024 MG)

BICISATE LABELLING KIT CRS (1024 MG)

NA

DISCOVER
Benserazide for peak identification

Benserazide for peak identification

14919-77-8

DISCOVER
MELOXICAM CRS (50 MG)

MELOXICAM CRS (50 MG)

71125-38-7

DISCOVER
MEFENAMIC ACID IMPURITY A CRS(100 MG)

MEFENAMIC ACID IMPURITY A CRS(100 MG)

87-59-2

DISCOVER
FLUVASTATIN FOR SYSTEM SUITABILITY CRS (0.5 MG)

FLUVASTATIN FOR SYSTEM SUITABILITY CRS (0.5 MG)

93957-55-2

DISCOVER
METHYLDOPA FOR SYSTEM SUITABILITY CRS (0.024 MG)

METHYLDOPA FOR SYSTEM SUITABILITY CRS (0.024 MG)

41372-08-1

DISCOVER